Halozyme Therapeutics Earnings
NASDAQ: HALOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Next earnings date
Mon, Nov 2, 2026
Fiscal period
Sep/2026
EPS estimate
$2.13
Halozyme Therapeutics earnings summary
Halozyme Therapeutics is scheduled to report Sep/2026 earnings on Nov 2, 2026, with analysts expecting EPS of $2.13. In its most recent report on Aug 6, 2026 (Q2 2026), HALO posted EPS of $1.90. Revenue for the quarter was $481.0 million.
Quarterly EPS is up 42.9% from the same quarter a year earlier. Across the last 16 reports, HALO shares moved an average of 5.0% (in either direction) in the first trading session after results, rising 10 times and falling 6 times.
Summary generated from market data by MetaCap's automated system. Methodology
HALO earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 6, 2026 | — | $1.90 | — | -4.3% |
| May 11, 2026 | — | $1.22 | — | +1.8% |
| Feb 17, 2026 | — | $-1.13 | — | -2.0% |
| Nov 3, 2025 | — | $1.43 | — | +2.6% |
| Aug 5, 2025 | — | $1.33 | — | +6.9% |
| May 6, 2025 | — | $0.93 | — | -21.0% |
| Feb 18, 2025 | — | $1.06 | — | +2.4% |
| Oct 31, 2024 | — | $1.05 | — | +6.7% |
| Aug 6, 2024 | — | $0.72 | — | +7.6% |
| May 7, 2024 | — | $0.60 | — | +3.6% |
| Feb 20, 2024 | — | $0.64 | — | +1.4% |
| Nov 6, 2023 | — | $0.61 | — | +7.2% |
| Aug 8, 2023 | — | $0.56 | — | -1.1% |
| May 9, 2023 | — | $0.29 | — | +2.7% |
| Feb 21, 2023 | — | $0.41 | — | -6.4% |
| Nov 8, 2022 | — | $0.44 | — | -1.9% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.